title: Frequency of BRCA mutations in primary peritoneal carcinoma in Israeli Jewish women.
abstract: OBJECTIVE
  The aim of the present study was to compare demographic and clinical characteristics of primary peritoneal carcinoma (PPC) to ovarian carcinoma (OvC) with regard to BRCA mutation frequencies.
  
  
  METHODS
  Incident cases of histologically confirmed cancer of the ovary or peritoneum diagnosed in Israeli Jewish women between March 1, 1994, and June 30, 1999, were identified within the framework of an ongoing nationwide epidemiological study of these neoplasms in Israel. The present study comprises 609 (81.5% of 747) Jewish women with epithelial stage III-IV OvC and 68 (77.3% of 88) Jewish women with PPC who were genetically tested for the BRCA mutations. Data from each patient were collected by the aid of a prestructured questionnaire and medical records. Blood samples or tumor tissue was tested for the 185delAG and 5382insC mutations in BRCA1 and the 6174delT mutations in BRCA2.
  
  
  RESULTS
  A carrier rate of 28% of any BRCA 1/2 mutation was observed among the PPC group and of 30% among the invasive stage III-IV OvC. No differences were found between PPC and OvC neither in the overall distribution of BRCA1/2 mutation carrier rates nor according to type of mutation, age, ethnic origin, and histologic subtype. Among women with a positive family history, a higher rate of mutation carriers was observed in the PPC group compared to the OvC group (72.7 vs 43.8%, respectively, P = 0.07).
  
  
  CONCLUSIONS
  The similar frequency distribution of BRCA1/2 mutations in PPC and OvC observed in the present study indicates that these mutations may predispose to PPC as well and that this neoplasm is part of the hereditary breast-ovarian cancer syndrome.
authors.affiliation: Gynecologic Oncology Unit, Department Of Obstetrics and Gynecology, E. Wolfson Medical Center, Holon, Israel. joseph12@internet-zahav.net
authors.forename: J
authors.initials: J
authors.lastname: Menczer
authors.forename: A
authors.initials: A
authors.lastname: Chetrit
authors.forename: G
authors.initials: G
authors.lastname: Barda
authors.forename: F
authors.initials: F
authors.lastname: Lubin
authors.forename: Y
authors.initials: Y
authors.lastname: Fishler
authors.forename: M
authors.initials: M
authors.lastname: Altaras
authors.forename: H
authors.initials: H
authors.lastname: Levavi
authors.forename: J P
authors.initials: JP
authors.lastname: Struewing
authors.forename: S
authors.initials: S
authors.lastname: Sadetzki
authors.forename: B
authors.initials: B
authors.lastname: Modan
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D005260:Female; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D006801:Humans; D007557:Israel / Q000453:epidemiology; D007585:Jews / Q000235:genetics*; D008875:Middle Aged; D009154:Mutation; D010051:Ovarian Neoplasms / Q000453:epidemiology / Q000235:genetics; D010534:Peritoneal Neoplasms / Q000453:epidemiology / Q000235:genetics*